March 02, 2015 12:11 AM ET

Diversified Consumer Services

Company Overview of The Scripps Research Institute

Company Overview

The Scripps Research Institute is an educational institution that offers graduate programs and postdoctoral fellows in biological and chemical sciences. It also provides programs for high school and middle school students, teachers, and undergraduates. The institution was formerly known as Scripps Institutions of Medicine and Science. The Scripps Research Institute was founded in 1991 and is based in La Jolla, California.

10550 North Torrey Pines Road

La Jolla, CA 92037

United States

Founded in 1991

Phone:

858-784-1000

Key Executives for The Scripps Research Institute

President
Age: 63
Executive Vice President and Chief Scientific Officer
Senior Vice President, Chief Financial Officer, and Treasurer
Professor and Director of Neurological Research Center
Senior Director of Business Development
Compensation as of Fiscal Year 2014.

The Scripps Research Institute Key Developments

The Scripps Research Institute and the University of California Develops a Powerful New System

The Scripps Research Institute (TSRI) and the University of California (UC) San Diego have developed a powerful new system for studying how proteins and other biological molecules form and lose their natural folded structures. Using the new system, researchers can force a sample of molecules to unfold and refold by boosting and then dropping the temperature, so quickly that even some of the fastest molecular folding events can be tracked.

The Scripps Research Institute Reports Positive New Clinical Data on Drug Candidate

The Scripps Research Institute reported positive new clinical data were released on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI). According to results released from a Phase 2 study of 199 patients with active, moderate to severe disease, the drug candidate RPC1063 has potential to significantly improve the treatment paradigm for ulcerative colitis patients. The latest results show that, after eight weeks of treatment with a 1 mg dose of RPC1063, 16.4% of patents were in clinical remission, as compared to 6.2% of patients on placebo. The clinical trial, sponsored by Receptos Inc., the San Diego biotechnology company now developing the drug, also showed that RPC1063 was generally well tolerated. Ulcerative colitis is a chronic condition that involves inflammation and sores in the inner lining of the digestive tract. Ulcerative colitis is an inflammatory bowel disease, which, along with Crohn's disease, affects more than one million people nationwide, according to the U.S. Centers for Disease Control and Prevention. Some people have mild disease, while others are affected with life-threatening complications. While existing medications for ulcerative colitis do help some patients, 23 to 45% of ulcerative colitis sufferers progress and eventually require surgical removal of all or part of the colon, according to the Crohn's and Colitis Foundation of America. The drug candidate RPC1063 was derived from a screening "hit" from the National Institutes of Health molecular library at Scripps Florida's Molecular Screening Center, using assay technology from the Rosen lab in La Jolla. The Roberts and Rosen labs then developed significant medicinal chemistry to turn that hit into a validated lead, and then ultimately a drug candidate. TSRI then licensed the compound to Receptos, which is developing RPC1063 for approval by the U.S. Food and Drug Administration. The latest results come from Receptos's multi-national, multi-center, double-blind, randomized, placebo-controlled study investigating the effect of two active doses of RPC1063 versus placebo for the treatment of moderately to severely active ulcerative colitis.

Scripps Florida Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM

Scripps Florida Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Dawn Johnson, Senior Director, Florida Operations.

Similar Private Companies By Industry

Company Name Region
30hands Learning, Inc. United States
iBidMotors LLC United States
The Cavanagh Law Firm, P.A. United States
Xtermite, Inc. United States
Texas Oil X Change, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
June 16, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Scripps Research Institute, please visit www.scripps.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.